KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
This guideline cites 8 of the 58 landmark trials in our Nephrology register.
- Issued by
- KDIGO
- Year
- 2021
- Source
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kidney Int. 2021;100(4S):S1–S276.doi 10.1016/j.kint.2021.05.021
The 2021 glomerular-diseases guideline is the umbrella document for the whole group — minimal-change disease, FSGS, membranous nephropathy, IgA nephropathy, lupus nephritis, ANCA-associated vasculitis, anti-GBM disease, membranoproliferative patterns and infection-related GN — organised around biopsy-anchored diagnosis, immunosuppression and supportive care. KDIGO is retiring it chapter by chapter, and four chapters are already superseded: lupus nephritis and ANCA-associated vasculitis (both 2024), IgA nephropathy/IgA vasculitis and childhood nephrotic syndrome (both 2025). For those diseases the newer standalone guidelines govern. The membranous, FSGS, minimal-change, C3G/MPGN, infection-related and anti-GBM chapters remain in force. Register trials are grouped by disease below; the ones published after 2021 — and therefore not available to this guideline — are listed separately.
Membranous nephropathy2
- 2019MENTORNephrology · Glomerular · Membranous nephropathyIn 130 patients with membranous nephropathy at moderate-to-high risk, rituximab achieved more complete or partial remission at 24 months than cyclosporine.60% vs 20%Read →
- 1984PonticelliNephrology · Glomerular · Membranous nephropathyIn 62 patients with idiopathic membranous nephropathy, alternating monthly methylprednisolone and a cytotoxic agent increased remission of nephrotic syndrome compared with supportive care.72% vs 30%Read →
Lupus nephritis3
- 2021AURORA 1Nephrology · Glomerular · Lupus nephritisIn 357 patients with active lupus nephritis, adding voclosporin to MMF and low-dose steroids increased complete renal response at week 52 compared with placebo.OR 2.6595% CI 1.64-4.27Read →
- 2020BLISS-LNNephrology · Glomerular · Lupus nephritisIn 448 patients with active lupus nephritis, adding belimumab to standard therapy increased renal response at week 104 compared with placebo.OR 1.55CI 1.04-2.32Read →
- 2009ALMSNephrology · Glomerular · Lupus nephritisIn 370 patients with active lupus nephritis, mycophenolate mofetil was non-inferior for induction response and superior for maintenance versus cyclophosphamide then azathioprine.Read →
ANCA-associated vasculitis3
- 2021ADVOCATENephrology · Glomerular · ANCA vasculitisIn 331 patients with ANCA-associated vasculitis, the oral C5a-receptor antagonist avacopan improved sustained remission at week 52 compared with a tapering prednisone regimen.65.7% vs 54.9%Read →
- 2020PEXIVAS CoreNephrology · Glomerular · ANCA vasculitisIn 704 patients with severe ANCA-associated vasculitis, plasma exchange did not reduce death or end-stage kidney disease compared with no plasma exchange.HR 0.8695% CI 0.65-1.13Read →
- 2010RAVE CoreNephrology · Glomerular · ANCA vasculitisIn 197 patients with severe ANCA-associated vasculitis, rituximab was non-inferior for inducing remission compared with cyclophosphamide.64% vs 53%Read →
Published since the guideline4
- 2025APPLAUSE-IgANNephrology · Glomerular · IgA nephropathyIn 250 patients with IgA nephropathy and persistent proteinuria, the factor-B inhibitor iptacopan reduced proteinuria compared with placebo.Read →
- 2023NefIgArdNephrology · Glomerular · IgA nephropathyIn 364 patients with IgA nephropathy on optimised RAS blockade, targeted-release budesonide preserved eGFR and reduced proteinuria compared with placebo.Read →
- 2023PROTECT 2023Nephrology · Glomerular · IgA nephropathyIn 404 patients with IgA nephropathy and proteinuria despite maximal RAS blockade, sparsentan reduced proteinuria compared with irbesartan.-49.8% vs -15.1%Read →
- 2023DUPLEXNephrology · Glomerular · FSGSIn 371 patients with focal segmental glomerulosclerosis, sparsentan reduced proteinuria but did not significantly improve eGFR slope compared with irbesartan.Read →
Cited landmark trials not yet in the register6
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2015STOP-IgAN
Immunosuppression on top of supportive care in IgA nephropathy: no benefit on eGFR loss.
- 2017TESTING
Methylprednisolone in IgA nephropathy — efficacy at the price of serious infection; the dose was later reduced.
- 2002Euro-Lupus Nephritis Trial
Low-dose intravenous cyclophosphamide as effective as the high-dose NIH regimen.
- 2014MAINRITSAN
Rituximab beat azathioprine for maintaining remission in ANCA-associated vasculitis.
- 2007MEPEX
Plasma exchange in severe renal ANCA vasculitis — the trial PEXIVAS later overturned.
- 2017GEMRITUX
Rituximab plus supportive care in membranous nephropathy.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.